3Silva RP, Barbosa PH, Kimura OS, et al. Prevalance of anemia and its association with cardio-renal syndrome[J]. Int J Cardiol, 2007, 120(2).-232-236.
4Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin[J]. Nature, 1985, 313(28) :806-810.
5Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview[J]. Am J Health Syst Pharm, 2007,64(13 suppt 8) : S3-7, quiz S23-25.
6Hampl H, Hennig L, Rosenberger C, et al. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients[J]. Am J Nephrol, 2005, 25 (3) : 211-220.
7Robinson BM, Joffe MM, Berns JS,et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time[J]. Kidney Int, 2005, 68(5) : 2323-2330.
8Covic A, Mardare NG, Ardeleanu S, et al. Serial eehocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation[J]. J Nephrol, 2006, 19 (6) : 783-793.
9Pljesa S. Possible complications of erythropoietin therapy in patients with chronic renal failure[J]. Med Pregl, 2004, 57 (5-6) :254-257.
10Hayashi T,Suzuki A,Shiji T.Cardiovascular effect of normalizing the hematocdt level during erythropietin therapy in predialysis patients with chronic renal failure[J].Am J Kidney Dis,2000,35 (2):250-252.
